- 1782-P - Phase 1b Study of AMPK/Mitochondrial Activator ATX-304 in Prediabetic Obese Participants [Board No. 1782]
-
Poster Hall (Halls D-E)1782-P
R.I.Thieroff-ekerdt: Employee; Current; Cambrian Biopharma. D.Jacobs: Employee; Current; Cambrian Biopharma. J.Hall: None. E.J.Schneider: Employee; Current; Cambrian BioPharma, Amplifier Therapeutics AB. J.Ainscough: Employee; Current; Cambrian Biopharma. J.Peyer: Board Member; Current; Cambrian Biopharma. T.Heise: Consultant; Current; Gan & Lee Pharmaceuticals, i2o Therapeutics, Other - Travel Grants; Current; Zealand Pharma A/S, Research Support; Current; Betagenon AB, Civica, Corteria Pharmaceuticals, DioGenX, ENYO Pharma, Gan & Lee Pharmaceuticals, Nanexa, Neodyne Biosciences, Sam Chun Dang, Sun Pharmaceutical Industries Ltd., Zealand Pharma A/S, AstraZeneca, Biocon, Eli Lilly and Company, Novo Nordisk, Roche Diagnostics, Research Support; Ended; Afon Technology, Cytoki Pharma, Liom, Speaker's Bureau; Current; Eli Lilly and Company, Novo Nordisk.Type
Enter Note
Go to previous page in this tab
Session
